文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma.

作者信息

Liu Juan, Zhang Cen, Lin Meihua, Zhu Wei, Liang Yingjian, Hong Xuehui, Zhao Yuhan, Young Ken H, Hu Wenwei, Feng Zhaohui

机构信息

Department of Radiation Oncology.

出版信息

Oncotarget. 2014 May 15;5(9):2635-47. doi: 10.18632/oncotarget.1862.


DOI:10.18632/oncotarget.1862
PMID:24797434
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4058033/
Abstract

The tumor suppressor p53 and its signaling pathway play a critical role in tumor prevention. As a direct p53 target gene, the role of glutaminase 2 (GLS2) in tumorigenesis is unclear. In this study, we found that GLS2 expression is significantly decreased in majority of human hepatocellular carcinoma (HCC). Restoration of GLS2 expression in HCC cells inhibits the anchorage-independent growth of cells and reduces the growth of HCC xenograft tumors. Interestingly, we found that GLS2 negatively regulates the PI3K/AKT signaling, which is frequently activated in HCC. Blocking the PI3K/AKT signaling in HCC cells largely abolishes the inhibitory effect of GLS2 on the anchorage-independent cell growth and xenograft tumor growth. The GLS2 promoter is hypermethylated in majority of HCC samples. CpG methylation of GLS2 promoter inhibits GLS2 transcription, whereas reducing the methylation of GLS2 promoter induces GLS2 expression. Taken together, our results demonstrate that GLS2 plays an important role in tumor suppression in HCC, and the negative regulation of PI3K/AKT signaling contributes greatly to this function of GLS2. Furthermore, hypermethylation of GLS2 promoter is an important mechanism contributing to the decreased GLS2 expression in HCC.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/63762139aa0b/oncotarget-05-2635-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/9652d910fb93/oncotarget-05-2635-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/fd08707ddd61/oncotarget-05-2635-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/a3a332dc76c0/oncotarget-05-2635-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/a47096b980ad/oncotarget-05-2635-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/5f36275db7cb/oncotarget-05-2635-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/ab21a3394396/oncotarget-05-2635-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/63762139aa0b/oncotarget-05-2635-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/9652d910fb93/oncotarget-05-2635-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/fd08707ddd61/oncotarget-05-2635-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/a3a332dc76c0/oncotarget-05-2635-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/a47096b980ad/oncotarget-05-2635-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/5f36275db7cb/oncotarget-05-2635-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/ab21a3394396/oncotarget-05-2635-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988b/4058033/63762139aa0b/oncotarget-05-2635-g007.jpg

相似文献

[1]
Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma.

Oncotarget. 2014-5-15

[2]
FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.

Oncol Rep. 2013-7-5

[3]
MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma.

Carcinogenesis. 2014-10-3

[4]
DNA methylation-mediated silencing of Neuronatin promotes hepatocellular carcinoma proliferation through the PI3K-Akt signaling pathway.

Life Sci. 2023-1-1

[5]
MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.

Cancer Sci. 2017-4

[6]
Methylation-regulated tumor suppressor gene PDE7B promotes HCC invasion and metastasis through the PI3K/AKT signaling pathway.

BMC Cancer. 2024-5-22

[7]
The silencing of Pokemon attenuates the proliferation of hepatocellular carcinoma cells in vitro and in vivo by inhibiting the PI3K/Akt pathway.

PLoS One. 2012-12-26

[8]
EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis.

Apoptosis. 2024-8

[9]
VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.

Oncogene. 2019-10-11

[10]
PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway.

Oncol Rep. 2010-6

引用本文的文献

[1]
UPLC-MS/MS Metabolomics Reveals Babao Dan's Mechanisms in MASH Treatment with Integrating Network Pharmacology and Molecular Docking.

Pharmaceuticals (Basel). 2025-7-25

[2]
Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications.

Front Immunol. 2025-4-30

[3]
Metabolic reprogramming and immunological changes in the microenvironment of esophageal cancer: future directions and prospects.

Front Immunol. 2025-1-24

[4]
GLS2 reduces the occurrence of epilepsy by affecting mitophagy function in mouse hippocampal neurons.

CNS Neurosci Ther. 2024-10

[5]
Targeting amino acid-metabolizing enzymes for cancer immunotherapy.

Front Immunol. 2024

[6]
CD87-targeted BiTE and CAR-T cells potently inhibit invasive nonfunctional pituitary adenomas.

Sci China Life Sci. 2024-10

[7]
Glutaminase - A potential target for cancer treatment.

Biomedicine (Taipei). 2024-6-1

[8]
Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression.

Crit Rev Biochem Mol Biol. 2024

[9]
Ferroptosis in hepatocellular carcinoma, from mechanism to effect.

Front Oncol. 2024-3-5

[10]
Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment.

Front Pharmacol. 2024-3-6

本文引用的文献

[1]
Tumour-associated mutant p53 drives the Warburg effect.

Nat Commun. 2013

[2]
Hepatocellular carcinoma.

Lancet. 2012-2-20

[3]
DNA methylation detection: bisulfite genomic sequencing analysis.

Methods Mol Biol. 2011

[4]
Global cancer statistics.

CA Cancer J Clin. 2011-2-4

[5]
CNV analysis using TaqMan copy number assays.

Curr Protoc Hum Genet. 2010-10

[6]
Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway.

Genes Cancer. 2010-5-15

[7]
Negative regulation of tumor suppressor p53 by microRNA miR-504.

Mol Cell. 2010-6-11

[8]
The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein.

Trends Cell Biol. 2010-7

[9]
Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function.

Proc Natl Acad Sci U S A. 2010-4-8

[10]
Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species.

Proc Natl Acad Sci U S A. 2010-3-29

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索